References
- Gray CM, Morris L, Murray J, et al. Identification of cell subsets expressing intracytoplasmic cytokines within HIV-1-infected lymph nodes. Aids 1996; 10(13): 1467–1475
- Gray CM, Schapiro JM, Winters MA, Merigan IC. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses 1998; 14(7): 561–569
- Gray CM, Lawrence J, Schapiro J M, et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in indi-viduals receiving highly active antiretroviral therapy (HAART). J Immunol 1999; 162(3): 1780–1788
- Gray CM, IC Merigan. Use of peptide/MHC tetramers to visualize, track, and chracterize class l-restricted anti-HIV 1-cell responses, pp315-331. In: Cossarizza A, Kaplan D, eds. Cellular Aspects of HIV Infection. Wiley & Sons, 1999
- Gray CM, Lawrence J, Ranheim EA, et al. Highly active antiretroviral therapy results in HIV type 1 suppres-sion in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. AIDS Res Hum Retroviruses 2000; 16(14): 1357–1369
- Van der Ryst E, Gray C, Williamson C, et al. Promoting HIV vaccine research and development in Southern Africa.S Afr Med J 1997; 87:1015–1016
- Morris L, Van der Ryst E, Gray C, Williamson C. Should South Africa be preparing for HIV-1 vaccine trials? S Afr Med J 1997; 87: 285–290